Last $69.85 USD
Change Today +0.25 / 0.36%
Volume 1.8M
BMRN On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

biomarin pharmaceutical inc (BMRN) Key Developments

BioMarin Pharmaceutical Inc. Presents at Bank of America Merrill Lynch Global Healthcare Conference, Sep-17-2014

BioMarin Pharmaceutical Inc. Presents at Bank of America Merrill Lynch Global Healthcare Conference, Sep-17-2014 . Venue: Bank of America Merrill Lynch Financial Centre, London, United Kingdom.

BioMarin Pharmaceutical Inc. Presents at J.P. Morgan 5th Annual U.S. All Stars Conference, Sep-16-2014

BioMarin Pharmaceutical Inc. Presents at J.P. Morgan 5th Annual U.S. All Stars Conference, Sep-16-2014 . Venue: J.P. Morgan Office, 25 Bank Street, Canary Wharf, London E14 5JP, United Kingdom.

BioMarin Pharmaceutical Revised Earnings Guidance for 2014

BioMarin Pharmaceutical Inc. announced its sale of the Rare Pediatric Disease Priority Review Voucher (the PRV) that the Company received in connection with the approval of VIMIZIM . In consideration for the sale of the PRV, the Company received $67.5 million from Regeneron Ireland (Regeneron), an indirect, wholly-owned subsidiary of Regeneron Pharmaceuticals Inc. The Company also announced in the Press Release updated full year 2014 revenue guidance, as of July 30, 2014, which included proceeds from the one-time sale of the PRV to Regeneron. The Company has since completed its evaluation of the transaction under the relevant U.S. Generally Acceptance Accounting Principles (U.S. GAAP) guidance and has determined that the appropriate classification of the transaction is a Gain on the Sale of Intangible Assets within the operating section of the Company's Statement of Comprehensive Loss for the period. As a result of this determination, the Company is adjusting previously announced full year 2014 revenue guidance to exclude from Total BioMarin Revenues the $67.5 million gain from the sale of the PRV. As a result of this adjustment, Total BioMarin Revenues decreased from a range of $745 million to $765 million to a range of $680 million to $700 million, inclusive of the Company's net product revenues, collaboration agreement revenues, royalty, license and other revenues. This change does not impact product revenue, GAAP or Non-GAAP earnings guidance, only the 2014 Total BioMarin Revenue guidance.

BioMarin Pharmaceutical Inc. Presents at Citi's 9th Annual Biotech Conference, Sep-04-2014 11:00 AM

BioMarin Pharmaceutical Inc. Presents at Citi's 9th Annual Biotech Conference, Sep-04-2014 11:00 AM. Venue: The Mandarin Oriental Boston, 776 Boylston Street, Boston, MA 02119, United States. Speakers: Daniel P. Maher, Senior Vice President of Product Development.

BioMarin Pharmaceutical Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 11:45 AM

BioMarin Pharmaceutical Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 11:45 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Jean-Jacques Bienaimé, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMRN:US $69.85 USD +0.25

BMRN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $46.73 USD +0.63
Amarin Corp PLC $1.30 USD -0.05
Dendreon Corp $1.50 USD +0.08
Jazz Pharmaceuticals PLC $163.64 USD +0.41
Spectrum Pharmaceuticals Inc $8.14 USD +0.01
View Industry Companies
 

Industry Analysis

BMRN

Industry Average

Valuation BMRN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.3x
Price/Book 7.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOMARIN PHARMACEUTICAL INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.